Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Ioannis Parodis

Showing results (41-50 of 189) with videos related to

Pageof 19
Sort By:
Journal of Clinical Medicine|August 26, 2023
Intracardiac Thrombi in Morbus Adamantiades-Behçet in Two Swedish PatientsRaffaele Da Mutten, Alexander Borg, Katerina Chatzidionysiou, et al.
Kidney International Reports|October 21, 2024
Response to Comment on "Effect of Belimumab on Preventing <i>De Novo</i> Renal Lupus Flares"Ioannis Parodis, Alvaro Gomez, Julius Lindblom, et al.
Best Practice & Research. Clinical Rheumatology|December 6, 2023
Reframing health disparities in SLE: A critical reassessment of racial and ethnic differences in lupus disease outcomesIoannis Parodis, Cristina Lanata, Dionysis Nikolopoulos, et al.
Autoimmunity Reviews|August 26, 2023
Is per-protocol kidney biopsy required in lupus nephritis?Ioannis Parodis, Gabriella Moroni, Marta Calatroni, et al.
Rheumatology (Oxford, England)|May 25, 2023
Determinants of neuropsychiatric flares in patients with systemic lupus erythematosus: results from five phase III trials of belimumabLeonardo Palazzo, Julius Lindblom, Nursen Cetrez, et al.
ARP Rheumatology|February 18, 2024
Lessons learnt from the recent recommendations for the non-pharmacological management of systemic sclerosisTânia Santiago, Ruben Fernandes, Ricardo Ferreira, et al.
Journal of Clinical Medicine|April 9, 2024
Factors Associated with Survival and Discontinuation of Anti-Malarial Agents in Systemic Lupus Erythematosus: Results from a Tertiary Swedish Referral CentreTomas Walhelm, Lina Wirestam, Yvonne Enman, et al.
Journal of Clinical Medicine|October 14, 2023
B Cell Tolerance and Targeted Therapies in SLEIoannis Parodis, Xuan Long, Mikael C I Karlsson, et al.
Rheumatology (Oxford, England)|February 25, 2024
Lupus Low Disease Activity State and organ damage in relation to quality of life in systemic lupus erythematosus: a cohort study with up to 11 years of follow-upIoannis Parodis, Thomas Haugli-Stephens, Annica Dominicus, et al.
Autoimmunity Reviews|August 14, 2019
Antimalarial agents diminish while methotrexate, azathioprine and mycophenolic acid increase BAFF levels in systemic lupus erythematosusBorja Hernández-Breijo, Alvaro Gomez, Sofia Soukka, et al.
Pageof 19

Showing results (41-50 of 189) with videos related to

Sort By:
Pageof 19
Journal of Clinical Medicine|August 26, 2023
Intracardiac Thrombi in Morbus Adamantiades-Behçet in Two Swedish PatientsRaffaele Da Mutten, Alexander Borg, Katerina Chatzidionysiou, et al.
Kidney International Reports|October 21, 2024
Response to Comment on "Effect of Belimumab on Preventing <i>De Novo</i> Renal Lupus Flares"Ioannis Parodis, Alvaro Gomez, Julius Lindblom, et al.
Best Practice & Research. Clinical Rheumatology|December 6, 2023
Reframing health disparities in SLE: A critical reassessment of racial and ethnic differences in lupus disease outcomesIoannis Parodis, Cristina Lanata, Dionysis Nikolopoulos, et al.
Autoimmunity Reviews|August 26, 2023
Is per-protocol kidney biopsy required in lupus nephritis?Ioannis Parodis, Gabriella Moroni, Marta Calatroni, et al.
Rheumatology (Oxford, England)|May 25, 2023
Determinants of neuropsychiatric flares in patients with systemic lupus erythematosus: results from five phase III trials of belimumabLeonardo Palazzo, Julius Lindblom, Nursen Cetrez, et al.
ARP Rheumatology|February 18, 2024
Lessons learnt from the recent recommendations for the non-pharmacological management of systemic sclerosisTânia Santiago, Ruben Fernandes, Ricardo Ferreira, et al.
Journal of Clinical Medicine|April 9, 2024
Factors Associated with Survival and Discontinuation of Anti-Malarial Agents in Systemic Lupus Erythematosus: Results from a Tertiary Swedish Referral CentreTomas Walhelm, Lina Wirestam, Yvonne Enman, et al.
Journal of Clinical Medicine|October 14, 2023
B Cell Tolerance and Targeted Therapies in SLEIoannis Parodis, Xuan Long, Mikael C I Karlsson, et al.
Rheumatology (Oxford, England)|February 25, 2024
Lupus Low Disease Activity State and organ damage in relation to quality of life in systemic lupus erythematosus: a cohort study with up to 11 years of follow-upIoannis Parodis, Thomas Haugli-Stephens, Annica Dominicus, et al.
Autoimmunity Reviews|August 14, 2019
Antimalarial agents diminish while methotrexate, azathioprine and mycophenolic acid increase BAFF levels in systemic lupus erythematosusBorja Hernández-Breijo, Alvaro Gomez, Sofia Soukka, et al.
Pageof 19